映恩生物-B(09606)于2026年5月26日公告，当日公司在香港联交所回购3万股普通股，占回购前已发行股本约0.0332%。该次回购价格介乎每股港币216.20元至218.40元，合计耗资约651.44万港元。回购股份将以库藏股形式持有。公司另披露，上述回购依据2025年6月20日通过的股份购回授权进行，授权可购回总数为8,803,626股。此次购回后授权余额为8,773,626股。
公告同时显示，自2026年5月4日至5月26日期间，公司因非发行人的董事行使根据首次公开发售前股权激励计划授予的期权而多次发行新股，累计增发126,600股普通股，发行价介乎每股港币214.8637元至271.4205元。于2026年5月26日收盘后，公司已发行股本增至90,524,414股，库藏股数为3万股，总股本为90,554,414股。
公司称，其所有股份购回及新股发行行为均遵守香港联合交易所有限公司证券上市规则及相关法律。公告由联席公司秘书袁佳丽签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.